A Randomized Phase II Study to Compare the Safety and Efficacy of Dalteparin vs. Rivaroxaban for Cancer-associated Venous Thromboembolism

Conditions:   Cancer-associated Thrombosis;   Esophageal Cancer;   Gastric Cancer;   Hepatobiliary Cancer;   Pancreatic Cancer;   Duodenal Cancer
Interventions:   Drug: Rivaroxaban;   Drug: Dalteparin
Sponsor:   Asan Medical Center
Recruiting - verified May 2017

http://ift.tt/2p0Z8Rf